MedTrace Logo

Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI

NCT01739127 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2016-05-25

No results posted yet for this study

Summary

The purpose of this study is to compare abdominal weight gain and fat distribution in people taking aripiprazole versus risperidone or quetiapine, to people not taking any of these antipsychotic medications.

Conditions

Interventions

DRUG

Aripiprazole

To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).

DRUG

Risperidone/Quetiapine

To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).

Sponsors & Collaborators

Principal Investigators

  • Alasdair M Barr, Ph.D. · The University of British Columbia

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01739127 on ClinicalTrials.gov